Xilio Therapeutics (XLO) Institutional Ownership $0.69 0.00 (0.00%) As of 07/3/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Xilio Therapeutics (NASDAQ:XLO)CurrentInstitutional OwnershipPercentage54.29%Number ofInstitutional Buyers(last 12 months)11TotalInstitutional Inflows(last 12 months)$10.93MNumber ofInstitutional Sellers(last 12 months)0 Get XLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data XLO Institutional Buying and Selling by Quarter Xilio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025ADAR1 Capital Management LLC40,000$29K0.0%N/A0.077% 4/29/2025Avantax Planning Partners Inc.150,399$109K0.0%N/A0.290% 2/17/2025Trustees of Columbia University in the City of New York249,635$238K0.0%N/A0.568% 2/17/2025Balyasny Asset Management L.P.343,230$328K0.0%+26.0%0.781% 2/17/2025Aptus Capital Advisors LLC41,000$39K0.0%N/A0.093% 2/14/2025Gilead Sciences Inc.9,105,451$8.70M0.6%N/A20.713% 2/13/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 2/13/2025Renaissance Technologies LLC296,617$283K0.0%+11.4%0.675% 2/12/2025Geode Capital Management LLC358,422$342K0.0%+6.0%0.815% 2/12/2025Takeda Pharmaceutical Co. Ltd.1,475,121$1.42M5.3%N/A3.356% Get the Latest News and Ratings for XLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/6/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 11/16/2024Geode Capital Management LLC338,192$266K0.0%+85.0%0.769% 8/12/2024XTX Topco Ltd33,289$32K0.0%N/A0.076% 8/9/2024Renaissance Technologies LLC295,000$280K0.0%+18.3%0.799% 5/6/2024Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690% 4/22/2024PFG Investments LLC30,000$32K0.0%N/A0.087% 2/15/2024Octagon Capital Advisors LP1,785,000$982K0.2%-23.0%6.481% 11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047% 8/15/2022Laurion Capital Management LP142,900$417K0.0%N/A0.520% 7/27/2022Bailard Inc.36,632$107K0.0%N/A0.133% 5/16/2022Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567% 5/12/2022Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594% 2/15/2022Davidson Kempner Capital Management LP29,000$458K0.0%N/A0.109% 2/14/2022Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078% 2/14/2022Ghisallo Capital Management LLC30,000$480K0.0%N/A0.113% 2/14/2022Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791% 2/11/2022Granite Point Capital Management L.P.10,000$160K0.0%N/A0.038% 2/9/2022AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504% 2/8/2022Northern Trust Corp63,034$1.01M0.0%N/A0.236% 2/7/2022Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803% 2/7/2022RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406% 2/2/2022New York State Common Retirement Fund5,568$89K0.0%N/A0.021% (Data available from 1/1/2016 forward) XLO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of XLO shares? During the previous two years, 14 institutional investors and hedge funds held shares of Xilio Therapeutics. The most heavily invested institutionals were Gilead Sciences Inc. ($8.70M), Takeda Pharmaceutical Co. Ltd. ($1.42M), Atlas Venture Life Science Advisors LLC ($1.07M), Octagon Capital Advisors LP ($982K), Geode Capital Management LLC ($342K), Balyasny Asset Management L.P. ($328K), and Renaissance Technologies LLC ($283K).Learn more on Xilio Therapeutics' institutional investors. What percentage of Xilio Therapeutics' stock is owned by institutional investors? 54.29% of Xilio Therapeutics' stock is owned by institutional investors. Learn more on XLO's institutional investor holdings. Which institutional investors have been buying Xilio Therapeutics' stock? Of the 12 institutional investors that purchased Xilio Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Gilead Sciences Inc. ($9.11M), Takeda Pharmaceutical Co. Ltd. ($1.48M), Trustees of Columbia University in the City of New York ($249.64K), Geode Capital Management LLC ($175.57K), Avantax Planning Partners Inc. ($150.40K), Raymond James Financial Inc. ($100.17K), and Renaissance Technologies LLC ($75.87K). How much institutional buying is happening at Xilio Therapeutics? Institutional investors have bought a total of 11,517,249 shares in the last 24 months. This purchase volume represents approximately $10.93M in transactions. Related Companies RAPT Institutional Ownership LXEO Institutional Ownership BDTX Institutional Ownership LYEL Institutional Ownership SKYE Institutional Ownership IMRX Institutional Ownership INMB Institutional Ownership NMRA Institutional Ownership FTLF Institutional Ownership GLSI Institutional Ownership This page (NASDAQ:XLO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
